NSCLC

Expert-driven insights on non–small cell lung cancer, highlighting biomarker-driven treatment strategies, targeted therapies, and immunotherapy across disease settings. Focuses on treatment sequencing, CNS management, and emerging clinical data to support personalized, evidence-based care.

TTLC 2026

Browse all TTLC 2026

TTLC 2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD, Susan Scott, MD

TTLC 2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MD, Sarah Goldberg, MD, MPH, Susan Scott, MD, Fawzi Abu Rous, MD, Julia Rotow, MD

TTLC 2026

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MD, Luis Raez, MD, FACP, FCCP, FASCO

TTLC 2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MD, Susan Scott, MD, Sarah Goldberg, MD, MPH, Fawzi Abu Rous, MD, Julia Rotow, MD

DATO-DXD

Browse all DATO-DXD

DATO-DXD

Ep. 5: CNS Activity and Sequencing Strategies for Datopotamab Deruxtecan in EGFR-Mutant NSCLC

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

DATO-DXD

Ep. 4: Datopotamab Deruxtecan in EGFR-Mutated NSCLC: Community-Based Monitoring and Toxicity Management

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

DATO-DXD

EP. 3: Monitoring, Dosing, and Rechallenge Strategies With Datopotamab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

DATO-DXD

Ep. 2: Managing Ocular Toxicity, Mucositis, and ILD With Datopotamab Deruxtecan in EGFR-Mutated NSCLC

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

NACLC 2025

Browse all NACLC 2025

NACLC 2025

EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

NACLC 2025

Ep. 4: Managing Toxicities in MARIPOSA: Mitigating Treatment-Related Adverse Events

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

NACLC 2025

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

NACLC 2025

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MD, Danny Nguyen, MD, Edgardo Santos Castillero, MD, FACP, FASCO, Eric Singhi, MD, Alexander Spira, MD, PhD, FACP, FASCO

ASCO 2025

Browse all ASCO 2025

ASCO 2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MD, Estelamari Rodriguez, MD, MPH, Helena Yu, MD

ASCO 2025

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MD, Joshua Sabari, MD

ASCO 2025

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD

ASCO 2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD, Susan Scott, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD